Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Wasik Lab, |
RCV003318464 | SCV004020307 | pathogenic | Malignant lymphoma, large B-cell, diffuse | 2023-07-25 | no assertion criteria provided | clinical testing | This variant was observed in a patient with DLBCL that presented in leukemic form, best classified as MCD/C5 DLBCL, an ABC subtype. Despite an initial good clinical response to BTK inhibitor ibrutinib, anti-CD20 antibody rituxan, alkylating agent bendamustine, and hematopoietic stem-cell transplant, the lymphoma relapsed, accompanied by morphologic and molecular evidence of disease progression. Mutations in FOXO1, a transcription factor, have been described in 10% of DLBCL (Sablon et al. 2022), and correlate with decreased overall survival in DLBCL treated with immunochemotherapy regimen containing anti-CD20 antibody. Novak et al. (2015) found that gene losses localized to 6q21-6q24.2, or gains at 3q13.12-3q9, (both were observed in the recurrent tumor) and 11q23.1-11q23.3, when combined with FOXO1 mutations, identified 77% of cases that failed to achieve event-free survival at 24 months. FOXO1 G161D was not present in this tumor at initial presentation, but was observed after relapse and has not been described before in DLBCL. The variant is predicted to affect the DNA binding domain. Pyrzynska et al. (2018) showed FOXO1 activating mutations possibly affect binding to the promoter of the MS4A1 gene encoding CD20 protein, and result in downregulation of CD20 expression; impairment of CD20 expression occurred in this tumor at relapse. |